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Nonalcoholic fatty liver disease (NAFLD) describes a non–
alcohol-induced cluster of conditions related to excessive
fat stored in the liver. Defined as 5% or more hepatic fat
content, NAFLD is prevalent, affecting ;25% of the
general population (1). Approximately 20% of individuals
with NAFLD have a more aggressive form of the disease,
termed nonalcoholic steatohepatitis (NASH), which is in
addition characterized by liver inflammation and extensive
scarring (cirrhosis) (1,2). NASH is a growing cause of liver
cancer and a leading indication for liver transplantation
(2). In addition, NAFLD and NASH are risk factors for
chronic kidney disease (3), type 2 diabetes (4), and car-
diovascular disease (5).
Despite being serious afflictions, NAFLD and in par-
ticular NASH face two major headwinds. One, they are
difficult to diagnose because they require liver biopsies
for conclusive diagnosis. Two, there are currently no
approved medications for treatment. Lifestyle interven-
tion to reduce body weight is the primary strategy to
manage the disease. However, while reducing caloric in-
take and increasing physical activity are obvious reme-
dies, such lifestyle modification has very limited efficacy in
the long run, with typically no more than 3–4% of weight
loss after 4 years (6). With a quickly growing population of
patients with NAFLD/NASH (2) and no approved thera-
pies, there is an unmet yet steadily increasing medical need
for safe and effective pharmacotherapy. Unfortunately,
resembling the quest for the Holy Grail, the development
of such a therapy seemed, as of today, a mission impos-
sible. In this issue of Diabetes, Cui et al. (7) make a signif-
icant step forward in developing a pharmacotherapy to
treat NAFLD and NASH. The authors developed a chemical
derivate of fibroblast growth factor 21 (FGF21) that
showed remarkable effects in melting away hepatic fat
in mice and monkeys.
FGF21 is an endocrine hormone that signals via a re-
ceptor complex consisting of FGF1 receptor and coreceptor
bKlotho. FGF21 is expressed in multiple peripheral tis-
sues, including liver, skeletal muscle, pancreas, and white
and brown adipose tissue (8). Interest in FGF21 exploded
with the discovery that pharmacological administration of
FGF21 to diabetic rodents and primates increased insulin
sensitivity, energy expenditure, and weight loss (6). More-
over, administration of an FGF21 analog to humans with
obesity significantly lowered body weight and decreased
LDL cholesterol and triglycerides while increasing HDL
cholesterol (9). These studies have spurred a number of
drug development programs designed to enhance FGF21
activity (10). Several preclinical animal studies have also
demonstrated that FGF21 could improve NAFLD/NASH
by reversing hepatic steatosis, counteracting obesity and
alleviating insulin resistance (11). The short half-life of
native FGF21 (;1–2 h) (12), however, has hampered
a successful translation of these FGF21 benefits into the
clinic.
In this issue of Diabetes, Cui et al. assess the efficacy of
a novel polyethylene glycolylated (PEGylated) and geneti-
cally modified long-acting FGF21 analog, called B1344, with
a half-life of $50 h, in improving NAFLD/NASH in obese
nonhuman primates and in lean mice. In one study, diet-
induced obese (DIO) male cynomolgus monkeys, with more
than 10% hepatic fat content, were injected twice weekly
with 0.5, 1.0, or 2.0 mg$kg21 of B1344 for 11 weeks. An
additional groupwas injected only once a weekwith the high
dose of B1344. All doses of B1344 reduced body weight by
;5% relative to vehicle-treated controls. Most importantly,
liver-specific end points, assessed by magnetic resonance
imaging and liver biopsies, demonstrated that B1344 re-
duced hepatic fat content by 40%, decreased scarring,
and lowered markers of hepatic inflammation (Fig. 1A).
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In the mouse study, a methionine- and choline-
deficient (MCD) diet was used to induce NASH without
obesity (13). After a lead-in period of 2 weeks on the
MCD diet, two doses (0.125 and 2 mg$kg21) of B1344
were tested by daily injections for up to 4 weeks. While
control mice developed patent NASH, B1344-treated
mice maintained low histological NASH scores, low liver
fat content, markedly lower circulating levels alanine
aminotransferase and aspartate aminotransferase, and
low expression of hepatic genes indicative of inflamma-
tion (Fig. 1B). The data from these two animal studies
suggest that B1344 can both partially reverse and pre-
vent NAFLD/NASH.
The data obtained from the cynomolgus monkeys are
the major strength of this work. The liver biopsies espe-
cially provide direct evidence that B1344 improves NASH.
Aminor limitation is that the DIOmonkeys presented only
mild NASH, evidenced by low immune cell infiltration. It is
also unclear whether B1344 elicits hepatic benefit via
direct actions in the liver or whether these effects are
partially affected by weight loss and enhanced glycemic
control. In addition to reducing weight, B1344 also im-
proved fasting glucose, glycated hemoglobin, and glucose
tolerance. A calorie-restricted control group to match the
B1344-induced weight loss could have provided additional
valuable information. Similarly, a head-to-head comparison
with native FGF21 would have added value to fully appre-
ciate the superior metabolic action of the long-acting FGF21
analog. The study in mice indicates that B1344 can prevent
NASH in a non–body-weight-related manner. While these
effects are promising, the MCD diet model has some
limitations. For one, the MCD diet does not reflect any
diet consumed by humans. In addition, already lean mice
lost 40% of their body weight in 8 weeks on theMCD diet in
the current study. This is in stark contrast to fatty liver
disease in humans, which is associated with obesity (14).
Nevertheless, the potent ability of B1344 to prevent a diet-
induced progression to NASH certainly warrants follow-up
investigations.
Collectively, the study by Cui et al. is an important step
forward in evaluating FGF21 analogs for the treatment of
NAFLD/NASH. Recently, another long-acting FGF21 an-
alog called pegbelfermin was evaluated in patients with
biopsy-confirmed NASH (15). While pegbelfermin re-
duced hepatic fat up to 30%, NASH end points were
not assessed with liver biopsies (15). Since liver fat and
NASH do not always correlate (16), it is significant that
Cui et al. now provide histological evidence that long-
acting FGF21 analogs can improve NASH in nonhuman
primates. To understand whether this is the case in humans
Figure 1—A new FGF21 analog improves NAFLD/NASH in nonhuman primates and mice. A: DIO male cynomolgus monkeys with .10%
hepatic fat content were injected twice a week for 11 weeks with B1344, a novel PEGylated and genetically modified long-acting FGF21
analog. Magnetic resonance imaging and liver biopsies demonstrated that B1344 reduced hepatic fat content by 40%, decreased scarring,
and lowered markers of hepatic inflammation. B: An MCD diet was used to induce NASH in lean mice. After 2 weeks on the MCD diet, mice
were treated with daily injections of vehicle or B1344 for up to 4 weeks. While control mice developed patent NASH, B1344-treated mice had
low histological NASH scores, low liver fat content, lower circulating levels of alanine aminotransferase and aspartate aminotransferase,
which are markers of liver injury, and low expression of hepatic genes indicative of inflammation.
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will be the next step in the quest to develop a pharmaco-
therapy for fatty liver disease.
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